MedPath

A study to use Artificial Intelligence to predict the outcomes of advanced stage Hodgkin Lymphoma

Not Applicable
Conditions
Health Condition 1: C819- Hodgkin lymphoma, unspecified
Registration Number
CTRI/2024/02/062294
Lead Sponsor
KOITA CENTRE FOR DIGITAL HEALTH(KCDH)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients diagnosed with advanced stage Hodgkins Lymphoma.

2. Patients whose baseline PET-CT reports are available.

3. Patients whose baseline paraffin block is available at TMH.

4. Age should be more than equal to 15 years.

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Baseline FDG PET-CT results will be used to measure the standardized uptake value of the tumour sites to assess the staging and severity of the disease. At the end of the first stage (Retrospective part), the AI system will learn about the tumour <br/ ><br>and will provide a score in a standardized form such as Deauville PET Criteria for its corresponding PET-CT scan #2. The predicted score and actual score from the retrospective study will be correlated.Timepoint: Retrospective Data analysis of PET CT done at the time of diagnosis.
Secondary Outcome Measures
NameTimeMethod
1. correlation of the prognostic model with respect to 2-year Event Free Survival and overall survival. <br/ ><br>2. comparing prognostic value of AI models against available gold standard IPS scores. <br/ ><br> <br/ ><br>Timepoint: 2years
© Copyright 2025. All Rights Reserved by MedPath